Revelyx Bio Launches to Advance YY003, an Investigational Recombinant Botulinum Toxin Type A in a Ready-to-Use Liquid Formulation

NASHVILLE, Tenn., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Revelyx Bio, Inc., a clinical-stage biopharmaceutical company, today announced its launch following an exclusive licensing agreement with Chongqing Claruvis Pharmaceutical Co., Ltd., for YY003, a ready-to-use liquid formulation of recombinant botulinum toxin type A (rBoNT/A). Under the terms of agreement, Revelyx holds exclusive rights to develop and commercialize YY003 for aesthetic and therapeutic indications globally, excluding mainland China, Hong Kong and Macau. Additionally, the company announced the appointment of Dustin Sjuts as Chief Executive Officer and member of its Board of Directors.